Compare Natera Inc. Common Stock (NTRA) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs BlackRock TCP Capital Corp — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while BlackRock TCP Capital Corp trades at $4.08 (market cap $335.61M). The key difference: Natera Inc. Common Stock is far larger — about 169.9× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and BlackRock TCP Capital Corp for 89 Days on average.
| NTRA | TCPC | |
|---|---|---|
Market Cap | $57.03B | $335.61M |
Volume | 1,131,157 | 435,738 |
Sector | Health | Financials |
52-Week High | $425.64 | $6.20 |
52-Week Low | $179.42 | $3.13 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $56.18B | $1.09B |
Dividend Yield | — | 19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TCPC trades at $3.98, showing no daily change. The stock exhibits a bullish technical signal, with moving averages supporting an uptrend. Recent Q2 2026 earnings beat expectations at $0.22 per share, and a $523 million portfolio sale has reduced leverage. However, fundamentals show negative revenue and net income trends, with a net loss of $88.93 million in 2025. The company maintains a dividend, with a $0.17 payment scheduled for September 2026.
The outlook is mixed. Positive technicals and strategic portfolio sales provide support, but persistent losses and a class action lawsuit pose significant risks. Analyst sentiment is cautious, with a majority recommending Hold. Investment potential hinges on the success of the strategic review and future profitability improvements amid ongoing financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
